SAMIL PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,050 KRW | -1.95% |
|
-1.31% | +35.07% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 125,732 | 128,479 | 128,907 | 106,418 | 108,894 | 96,901 |
| Enterprise Value (EV) 1 | 181,452 | 192,361 | 206,112 | 216,672 | 266,249 | 271,874 |
| P/E ratio | -12.7 x | 163 x | 93.9 x | -19.6 x | -3,837 x | 58.3 x |
| Yield | 0.49% | 0.71% | 0.73% | 0.96% | - | - |
| Capitalization / Revenue | 1.33 x | 1.06 x | 1.05 x | 0.79 x | 0.61 x | 0.49 x |
| EV / Revenue | 1.92 x | 1.59 x | 1.68 x | 1.61 x | 1.48 x | 1.38 x |
| EV / EBITDA | -88.7 x | 21.8 x | 19.2 x | 42.4 x | 29.6 x | 23 x |
| EV / FCF | -93.7 x | -19.6 x | -15.3 x | -6.53 x | -7.07 x | -9.88 x |
| FCF Yield | -1.07% | -5.1% | -6.53% | -15.3% | -14.2% | -10.1% |
| Price to Book | 2.24 x | 2.07 x | 2.03 x | 1.59 x | 0.88 x | 0.76 x |
| Nbr of stocks (in thousands) | 13,428 | 13,428 | 13,767 | 14,036 | 13,961 | 14,463 |
| Reference price 2 | 9,364 | 9,568 | 9,364 | 7,582 | 7,800 | 6,700 |
| Announcement Date | 3/14/19 | 3/12/20 | 3/11/21 | 3/14/22 | 3/16/23 | 3/14/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 94,600 | 121,107 | 122,999 | 134,247 | 179,676 | 196,346 |
| EBITDA 1 | -2,046 | 8,812 | 10,738 | 5,112 | 9,006 | 11,828 |
| EBIT 1 | -5,732 | 4,796 | 6,538 | 399.7 | 4,017 | 6,460 |
| Operating Margin | -6.06% | 3.96% | 5.32% | 0.3% | 2.24% | 3.29% |
| Earnings before Tax (EBT) 1 | -8,135 | 1,456 | 1,198 | -4,761 | 1,058 | 1,424 |
| Net income 1 | -8,563 | 786.3 | 1,341 | -5,347 | -28.29 | 1,664 |
| Net margin | -9.05% | 0.65% | 1.09% | -3.98% | -0.02% | 0.85% |
| EPS 2 | -736.8 | 58.55 | 99.70 | -386.6 | -2.033 | 115.0 |
| Free Cash Flow 1 | -1,936 | -9,807 | -13,459 | -33,164 | -37,685 | -27,525 |
| FCF margin | -2.05% | -8.1% | -10.94% | -24.7% | -20.97% | -14.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 45.45 | 68.18 | 68.18 | 72.73 | - | - |
| Announcement Date | 3/14/19 | 3/12/20 | 3/11/21 | 3/14/22 | 3/16/23 | 3/14/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 55,719 | 63,882 | 77,205 | 110,254 | 157,355 | 174,973 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -27.23 x | 7.25 x | 7.19 x | 21.57 x | 17.47 x | 14.79 x |
| Free Cash Flow 1 | -1,936 | -9,807 | -13,459 | -33,164 | -37,685 | -27,525 |
| ROE (net income / shareholders' equity) | -16% | 1.33% | 2.13% | -8.27% | -0.03% | 1.31% |
| ROA (Net income/ Total Assets) | -2.53% | 1.81% | 2.18% | 0.12% | 0.86% | 1.11% |
| Assets 1 | 338,730 | 43,519 | 61,598 | -4,474,196 | -3,285 | 149,855 |
| Book Value Per Share 2 | 4,177 | 4,621 | 4,616 | 4,776 | 8,830 | 8,838 |
| Cash Flow per Share 2 | 223.0 | 1,241 | 1,162 | 290.0 | 134.0 | 62.70 |
| Capex 1 | 3,704 | 13,891 | 17,020 | 32,828 | 48,481 | 24,244 |
| Capex / Sales | 3.92% | 11.47% | 13.84% | 24.45% | 26.98% | 12.35% |
| Announcement Date | 3/14/19 | 3/12/20 | 3/11/21 | 3/14/22 | 3/16/23 | 3/14/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +35.07% | 128M | |
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- A000520 Stock
- Financials Samil Pharmaceutical Co.,Ltd
